Biomarker Analysis for the Clustering of Benignant Nevi from Melanomas using Lipid Phenotype and the MALDI-8030 Dual Polarity Benchtop MALDI-TOF Mass Spectrometer

User Benefits

- Rapid and easy profiling of lipids in both positive and negative mode on affordable benchtop MALDI-8030. - MALDI-8030 compatibility with Oncofinder software provides excellent screening of biomarker for melanomas. - Reduction of the workload in high sample volume routine workflows is possible with the MALDI-8030.

Introduction

The MALDI-8030 is the latest benchtop MALDI-TOF mass spectrometer from Shimadzu, building on the affordable, compact and powerful MALDI-8020 with the ability to analyse samples in both positive and negative ion modes. In this note, we demonstrate how the MALDI-8030 can be used to conduct a clustering of benignant nevi from melanomas based on differences in extracted lipid profiles. The results obtained demonstrate the potential of this approach as a rapid biomarker screening tool. Oncofinder (IMG Pharma Biotech, Spain) is a research use only platform that enables the screening of lipid biomarkers present in tissue or liquid biopsies for the diagnosis, staging and prognosis of melanoma1. This panel of lipid biomarkers may be used for the rapid and accurate clustering of benignant nevi from melanomas by studying the lipid fingerprint using mass spectrometry and artificial intelligence. The combination of the power of mass spectrometry and machine learning also enables the Oncofinder platform to evaluate the lipid biomarkers potential for detection melanoma and prognostic capabilities. In collaboration with IMG Pharma Biotech, we have evaluated the performance of the Oncofinder software as a package with the MALDI-8030 using biomarker data obtained from the analysis of skin biopsy homogenates on MALDI-8030.

April 5, 2022 GMT